Compare Organon & Co. Common Stock (OGN) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Nuscale Power Corporation — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Nuscale Power Corporation trades at $5.66 (market cap $2.39B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Nuscale Power Corporation for 30 Days on average.
| OGN | SMR | |
|---|---|---|
Market Cap | $3.61B | $2.39B |
Volume | 1,808,049 | 42,309,613 |
Sector | Health | Industrials |
52-Week High | $13.81 | $53.43 |
52-Week Low | $5.70 | $5.83 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $11.03B | $1.32B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
NuScale Power (SMR) trades at $6.495, down 3.06% today, with bearish technical signals dominating despite some oversold RSI readings. The company shows severe financial strain with negative net income margins of -3,888.7% and operating cash flow deficits, though it maintains strong analyst support with a $11.25 consensus price target. Recent news highlights ongoing legal investigations and competitive pressures in the nuclear energy sector.
The stock faces significant fundamental challenges with massive losses and cash burn, but offers speculative upside if commercialization efforts succeed. Key risks include execution missteps, dilution concerns, and intense SMR competition. With 50% analyst buy ratings but bearish technicals, SMR represents a high-risk, high-reward opportunity in the emerging nuclear energy space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
